Segall Bryant & Hamill LLC Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Segall Bryant & Hamill LLC cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,472 shares of the company’s stock after selling 512 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Neurocrine Biosciences were worth $4,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Neurocrine Biosciences during the third quarter valued at approximately $553,000. Quest Partners LLC raised its holdings in Neurocrine Biosciences by 674.9% during the 3rd quarter. Quest Partners LLC now owns 3,495 shares of the company’s stock valued at $403,000 after buying an additional 3,044 shares during the last quarter. Swiss National Bank boosted its position in Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after buying an additional 4,100 shares during the period. AM Squared Ltd bought a new stake in Neurocrine Biosciences in the 3rd quarter worth $104,000. Finally, Archer Investment Corp increased its position in shares of Neurocrine Biosciences by 37.0% in the third quarter. Archer Investment Corp now owns 740 shares of the company’s stock valued at $85,000 after acquiring an additional 200 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Stock Up 0.5 %

Shares of NASDAQ NBIX opened at $125.65 on Friday. The firm’s 50-day moving average price is $118.55 and its 200-day moving average price is $132.13. Neurocrine Biosciences, Inc. has a 52-week low of $110.52 and a 52-week high of $157.98. The company has a market cap of $12.72 billion, a PE ratio of 33.51 and a beta of 0.35.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Barclays reduced their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Raymond James reiterated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, Guggenheim upped their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.